文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

肝癌中核苷酸还原酶亚基的预后和免疫潜力。

Prognostic and Immunological Potential of Ribonucleotide Reductase Subunits in Liver Cancer.

机构信息

Department of Radiation Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, Zhejiang 310003, China.

Department of Gastroenterology, Sir Run Run Shaw Hospital, Zhejiang University Medical School, Hangzhou 310016, China.

出版信息

Oxid Med Cell Longev. 2023 Jan 20;2023:3878796. doi: 10.1155/2023/3878796. eCollection 2023.

DOI:10.1155/2023/3878796
PMID:36713030
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9883104/
Abstract

BACKGROUND: Ribonucleotide reductase (RR) consists of two subunits, the large subunit RRM1 and the small subunit (RRM2 or RRM2B), which is essential for DNA replication. Dysregulations of RR were implicated in multiple types of cancer. However, the abnormal expressions and biologic functions of RR subunits in liver cancer remain to be elucidated. METHODS: TCGA, HCCDB, CCLE, HPA, cBioPortal, and GeneMANIA were utilized to perform bioinformatics analysis of RR subunits in the liver cancer. GO, KEGG, and GSEA were used for enrichment analysis. RESULTS: The expressions of RRM1, RRM2, and RRM2B were remarkably upregulated among liver cancer tissue both in mRNA and protein levels. High expression of RRM1 and RRM2 was notably associated with high tumor grade, high stage, short overall survival, and disease-specific survival. Enrichment analyses indicated that RRM1 and RRM2 were related to DNA replication, cell cycle, regulation of nuclear division, DNA repair, and DNA recombination. Correlation analysis indicated that RRM1 and RRM2 were significantly associated with several subsets of immune cell, including Th2 cells, cytotoxic cells, and neutrophils. RRM2B expression was positively associated with immune score and stromal score. Chemosensitivity analysis revealed that sensitivity of nelarabine was positively associated with high expressions of RRM1 and RRM2. The sensitivity of rapamycin was positively associated with high expressions of RRM2B. CONCLUSION: Our findings demonstrated high expression profiles of RR subunits in liver cancer, which may provide novel insights for predicting the poor prognosis and increased chemosensitivity of liver cancer in clinic.

摘要

背景：核苷酸还原酶（RR）由两个亚基组成，大亚基 RRM1 和小亚基（RRM2 或 RRM2B），这对于 DNA 复制是必不可少的。RR 的失调与多种类型的癌症有关。然而，肝癌中 RR 亚基的异常表达和生物学功能仍有待阐明。

方法：利用 TCGA、HCCDB、CCLE、HPA、cBioPortal 和 GeneMANIA 对肝癌中 RR 亚基进行生物信息学分析。GO、KEGG 和 GSEA 用于富集分析。

结果：RRM1、RRM2 和 RRM2B 在肝癌组织中的 mRNA 和蛋白水平均显著上调。RRM1 和 RRM2 的高表达与高肿瘤分级、高分期、总生存期和疾病特异性生存期短显著相关。富集分析表明，RRM1 和 RRM2 与 DNA 复制、细胞周期、核分裂调节、DNA 修复和 DNA 重组有关。相关性分析表明，RRM1 和 RRM2 与包括 Th2 细胞、细胞毒性细胞和嗜中性粒细胞在内的几种免疫细胞亚群显著相关。RRM2B 的表达与免疫评分和基质评分呈正相关。化疗敏感性分析表明，奈拉滨的敏感性与 RRM1 和 RRM2 的高表达呈正相关。雷帕霉素的敏感性与 RRM2B 的高表达呈正相关。

结论：我们的研究结果表明 RR 亚基在肝癌中呈现高表达谱，这可能为预测肝癌的不良预后和增加化疗敏感性提供新的思路。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a8f/9883104/637db82af9fa/OMCL2023-3878796.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a8f/9883104/4c4d8e529415/OMCL2023-3878796.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a8f/9883104/beab5bf0457c/OMCL2023-3878796.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a8f/9883104/8073092d6a2b/OMCL2023-3878796.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a8f/9883104/e6e06558538f/OMCL2023-3878796.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a8f/9883104/7b2fa02274a5/OMCL2023-3878796.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a8f/9883104/637db82af9fa/OMCL2023-3878796.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a8f/9883104/4c4d8e529415/OMCL2023-3878796.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a8f/9883104/beab5bf0457c/OMCL2023-3878796.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a8f/9883104/8073092d6a2b/OMCL2023-3878796.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a8f/9883104/e6e06558538f/OMCL2023-3878796.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a8f/9883104/7b2fa02274a5/OMCL2023-3878796.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a8f/9883104/637db82af9fa/OMCL2023-3878796.006.jpg

相似文献

[1]
Prognostic and Immunological Potential of Ribonucleotide Reductase Subunits in Liver Cancer.

Oxid Med Cell Longev. 2023

[2]
Ribonucleotide Reductase Requires Subunit Switching in Hypoxia to Maintain DNA Replication.

Mol Cell. 2017-4-20

[3]
P53 suppresses ribonucleotide reductase via inhibiting mTORC1.

Oncotarget. 2017-6-20

[4]
Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine.

BMC Cancer. 2013-11-12

[5]
The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53.

Cancer Res. 2003-10-15

[6]
Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.

Cancer. 2012-7-3

[7]
A Single Conserved Residue Mediates Binding of the Ribonucleotide Reductase Catalytic Subunit RRM1 to RRM2 and Is Essential for Mouse Development.

Mol Cell Biol. 2015-9-1

[8]
Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy.

Tumour Biol. 2014-12

[9]
Comprehensive bioinformatics analysis of ribonucleoside diphosphate reductase subunit M2(RRM2) gene correlates with prognosis and tumor immunotherapy in pan-cancer.

Aging (Albany NY). 2022-10-3

[10]
Ribonucleotide reductase subunit M2 predicts survival in subgroups of patients with non-small cell lung carcinoma: effects of gender and smoking status.

PLoS One. 2015-5-22

引用本文的文献

[1]
Exploring the effect and mechanism of fucoidan on liver cancer depending on network pharmacology and experimental verification.

Front Chem. 2025-7-16

[2]
RRM2 promotes liver metastasis of pancreatic cancer by stabilizing YBX1 and activating the TGF-beta pathway.

iScience. 2024-8-31

[3]
Exploring Ribosomal Genes as Potential Biomarkers of the Immune Microenvironment in Respiratory Syncytial Virus Infection.

Biochem Genet. 2025-4

[4]
DLD is a potential therapeutic target for COVID-19 infection in diffuse large B-cell lymphoma patients.

Apoptosis. 2024-10

[5]
Creatine kinase elevation in chronic hepatitis B patients with telbivudine therapy: influence of telbivudine plasma concentration and single nucleotide polymorphisms of TK2, RRM2B, and NME4.

Eur J Clin Pharmacol. 2024-7

本文引用的文献

[1]
Prognostic and predictive role of a metabolic rate-limiting enzyme signature in hepatocellular carcinoma.

Cell Prolif. 2021-10

[2]
Hepatocellular carcinoma.

Nat Rev Dis Primers. 2021-1-21

[3]
Cancer Statistics, 2021.

CA Cancer J Clin. 2021-1

[4]
RRM2 protects against ferroptosis and is a tumor biomarker for liver cancer.

Cancer Cell Int. 2020-12-7

[5]
The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis.

PLoS One. 2020-2-13

[6]
RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy.

BMC Urol. 2019-7-24

[7]
RRM1 expression and the clinicopathological characteristics of patients with non-small cell lung cancer treated with gemcitabine.

Onco Targets Ther. 2018-9-7

[8]
Molecular therapies and precision medicine for hepatocellular carcinoma.

Nat Rev Clin Oncol. 2018-10

[9]
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.

Hepatology. 2018-8

[10]
Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma.

Clin Cancer Res. 2017-4-25

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索